Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implications

References

Alexiou, T., Boon, W.M., Denton, D.A., Nicolantonio, R.D., Walker, L.L., McKinley, M.J., and Campbell, D.J. (2005). Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J. Hypertens. 23, 945–954.10.1097/01.hjh.0000166834.32817.41Search in Google Scholar

Alhenc-Gelas, F., Bouby, N., Richer, C., Potier, L., Roussel, R., and Marre, M. (2011). Kinins as therapeutic agents in cardiovascular and renal diseases. Curr. Pharm. Des. 17, 2654–2662.10.2174/138161211797416002Search in Google Scholar

Azizi, M., Boutouyrie, P., Bissery, A., Agharazii, M., Verbeke, F., Stern, N., Bura-Riviere, A., Laurent, S., Alhenc-Gelas, F., and Jeunemaitre, X. (2005). Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest. 115, 780–787.10.1172/JCI200523669Search in Google Scholar

Belanger, S., Bovenzi, V., Cote, J., Neugebauer, W., Amblard, M., Martinez, J., Lammek, B., Savard, M., and Gobeil, F., Jr. (2009). Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 30, 777–787.10.1016/j.peptides.2008.12.003Search in Google Scholar

Bell, R.M. and Yellon, D.M. (2003). Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J. Mol. Cell Cardiol. 35, 185–193.10.1016/S0022-2828(02)00310-3Search in Google Scholar

Bergaya, S., Meneton, P., Bloch-Faure, M., Mathieu, E., Alhenc-Gelas, F., Levy, B.I., and Boulanger, C.M. (2001). Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ. Res. 88, 593–599.10.1161/01.RES.88.6.593Search in Google Scholar PubMed

Bergaya, S., Hilgers, R.H., Meneton, P., Dong, Y., Bloch-Faure, M., Inagami, T., Alhenc-Gelas, F., Levy, B.I., and Boulanger, C.M. (2004). Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ. Res. 94, 1623–1629.10.1161/01.RES.0000131497.73744.1aSearch in Google Scholar PubMed

Bhat, M., Pouliot, M., Couture, R., and Vaucher, E. (2014). The kallikrein-kinin system in diabetic retinopathy. Prog. Drug Res. 69, 111–143.10.1007/978-3-319-06683-7_5Search in Google Scholar PubMed

Bodin, S., Chollet, C., Goncalves-Mendes, N., Gardes, J., Pean, F., Heudes, D., Bruneval, P., Marre, M., Alhenc-Gelas, F., and Bouby, N. (2009). Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int. 76, 395–403.10.1038/ki.2009.208Search in Google Scholar PubMed

Brown, N.J., Gainer, J.V., Murphey, L.J., and Vaughan, D.E. (2000). Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B₂ receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102, 2190–2196.10.1161/01.CIR.102.18.2190Search in Google Scholar PubMed

Cambien, F., Poirier, O., Lecerf, L., Evans, A., Cambou, J.P., Arveiler, D., Luc, G., Bard, J.M., Bara, L., Ricard, S., et al. (1992). Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359, 641–644.10.1038/359641a0Search in Google Scholar PubMed

Campbell, D.J., Kladis, A., and Duncan, A.M. (1994). Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23, 439–449.10.1161/01.HYP.23.4.439Search in Google Scholar PubMed

Carey, R.M., Wang, Z.Q., and Siragy, H.M. (2000). Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35, 155–163.10.1161/01.HYP.35.1.155Search in Google Scholar

Cicardi, M., Banerji, A., Bracho, F., Malbran, A., Rosenkranz, B., Riedl, M., Bork, K., Lumry, W., Aberer, W., Bier, H., et al. (2010). Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med. 363, 532–541.10.1056/NEJMoa0906393Search in Google Scholar PubMed PubMed Central

Cote, J., Savard, M., Bovenzi, V., Belanger, S., Morin, J., Neugebauer, W., Larouche, A., Dubuc, C., and Gobeil, F., Jr. (2009). Novel kinin B1 receptor agonists with improved pharmacological profiles. Peptides 30, 788–795.10.1016/j.peptides.2008.12.018Search in Google Scholar PubMed

Desposito, D., Potier, L., Chollet, C., Gobeil, F., Jr., Roussel, R., Alhenc-Gelas, F., Bouby, N., and Waeckel, L. (2015a). Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice. J. Pharmacol. Exp. Ther. 352, 218–226.10.1124/jpet.114.219196Search in Google Scholar PubMed

Desposito, D., Taveau, D., Zadigue, G., Adam, C., Bouby, N., Alhenc-Gelas, F., and Roussel, R. (2015b). Effect of pharmacological kinin receptor activation on brain damage and mortality in experimental cerebral ischemia in non-diabetic and diabetic mice. Hypertension 66, AP159.10.1161/hyp.66.suppl_1.p159Search in Google Scholar

Desposito, D., Chollet, C., Taveau, C., Descamps, V., Alhenc-Gelas, F., Roussel, R., Bouby, N., and Waeckel, L. (2016). Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade. Clin. Sci. (Lond.) 130, 45–56.10.1042/CS20150295Search in Google Scholar PubMed

Emanueli, C., Minasi, A., Zacheo, A., Chao, J., Chao, L., Salis, M.B., Straino, S., Tozzi, M.G., Smith, R., Gaspa, L. et al. (2001). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125–132.10.1161/01.CIR.103.1.125Search in Google Scholar PubMed

Erdos, E.G. (1990). Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 16, 363–370.10.1161/01.HYP.16.4.363Search in Google Scholar PubMed

Furchgott, R.F. and Vanhoutte, P.M. (1989). Endothelium-derived relaxing and contracting factors. FASEB J. 3, 2007–2018.10.1096/fasebj.3.9.2545495Search in Google Scholar

Griol-Charhbili, V., Messadi-Laribi, E., Bascands, J.L., Heudes, D., Meneton, P., Giudicelli, J.F., Alhenc-Gelas, F., and Richer, C. (2005). Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J. 19, 1172–1174.10.1096/fj.04-3508fjeSearch in Google Scholar PubMed

Huang, W., Gallois, Y., Bouby, N., Bruneval, P., Heudes, D., Belair, M.F., Krege, J.H., Meneton, P., Marre, M., Smithies, O. et al. (2001). Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc. Natl. Acad. Sci. USA 98, 13330–13334.10.1073/pnas.231476798Search in Google Scholar PubMed PubMed Central

Kakoki, M., Takahashi, N., Jennette, J.C., and Smithies, O. (2004). Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc. Natl. Acad. Sci. USA 101, 13302–13305.10.1073/pnas.0405449101Search in Google Scholar PubMed PubMed Central

Kakoki, M., Kizer, C.M., Yi, X., Takahashi, N., Kim, H.S., Bagnell, C.R., Edgell, C.J., Maeda, N., Jennette, J.C., and Smithies, O. (2006). Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J. Clin. Invest. 116, 1302–1309.10.1172/JCI26958Search in Google Scholar PubMed PubMed Central

Kakoki, M., McGarrah, R.W., Kim, H.S., and Smithies, O. (2007). Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA 104, 7576–7581.10.1073/pnas.0701617104Search in Google Scholar PubMed PubMed Central

Kayashima, Y., Smithies, O., and Kakoki, M. (2012). The kallikrein-kinin system and oxidative stress. Curr. Opin. Nephrol. Hypertens 21, 92–96.10.1097/MNH.0b013e32834d54b1Search in Google Scholar PubMed PubMed Central

Koid, S.S., Ziogas, J., and Campbell, D.J. (2014). Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism. Hypertension 63, 768–773.10.1161/HYPERTENSIONAHA.113.02902Search in Google Scholar PubMed

Krankel, N., Katare, R.G., Siragusa, M., Barcelos, L.S., Campagnolo, P., Mangialardi, G., Fortunato, O., Spinetti, G., Tran, N., Zacharowski, K. et al. (2008). Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ. Res. 103, 1335–1343.10.1161/CIRCRESAHA.108.179952Search in Google Scholar PubMed PubMed Central

Linz, W., Wiemer, G., Gohlke, P., Unger, T., and Scholkens, B.A. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47, 25–49.Search in Google Scholar

Liu, Y.H., Yang, X.P., Mehta, D., Bulagannawar, M., Scicli, G.M., and Carretero, O.A. (2000). Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am. J. Physiol. Heart Circ. Physiol. 278, H507–H514.10.1152/ajpheart.2000.278.2.H507Search in Google Scholar PubMed

Margolius, H.S., Geller, R.G., De Jong, W., Pisano, J.J., and Sjoerdsma, A. (1972). Urinary kallikrein excretion in hypertension. Circ. Res. 31 (Suppl. 2), 125–131.Search in Google Scholar

Marre, M., Jeunemaitre, X., Gallois, Y., Rodier, M., Chatellier, G., Sert, C., Dusselier, L., Kahal, Z., Chaillous, L., Halimi, S., et al. (1997). Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J. Clin. Invest. 99, 1585–1595.10.1172/JCI119321Search in Google Scholar PubMed PubMed Central

Meneton, P., Bloch-Faure, M., Hagege, A.A., Ruetten, H., Huang, W., Bergaya, S., Ceiler, D., Gehring, D., Martins, I., Salmon, G., et al. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc. Natl. Acad. Sci. USA 98, 2634–2639.10.1073/pnas.051619598Search in Google Scholar PubMed PubMed Central

Messadi, E., Vincent, M.P., Griol-Charhbili, V., Mandet, C., Colucci, J., Krege, J.H., Bruneval, P., Bouby, N., Smithies, O., Alhenc-Gelas, F., et al. (2010). Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J. 24, 4691–4700.10.1096/fj.10.165902Search in Google Scholar

Messadi-Laribi, E., Griol-Charhbili, V., Pizard, A., Vincent, M.P., Heudes, D., Meneton, P., Alhenc-Gelas, F., and Richer, C. (2007). Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J. Pharmacol. Exp. Ther. 323, 210–216.10.1124/jpet.107.124859Search in Google Scholar PubMed

Phipps, J.A. and Feener, E.P. (2008). The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney. Kidney Int. 73, 1114–1119.10.1038/ki.2008.9Search in Google Scholar PubMed

Pinto, Y.M., Bader, M., Pesquero, J.B., Tschope, C., Scholtens, E., van Gilst, W.H., and Buikema, H. (2000). Increased kallikrein expression protects against cardiac ischemia. FASEB J. 14, 1861–1863.10.1096/fj.99-1011fjeSearch in Google Scholar PubMed

Pons, S., Griol-Charhbili, V., Heymes, C., Fornes, P., Heudes, D., Hagege, A., Loyer, X., Meneton, P., Giudicelli, J.F., Samuel, J.L., et al. (2008). Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Eur. J. Heart Fail. 10, 343–351.10.1016/j.ejheart.2008.02.002Search in Google Scholar PubMed

Potier, L., Waeckel, L., Richer, C., Roussel, R., Bouby, N., and Alhenc-Gelas, F. (2013a). Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency. Biol. Chem. 394, 329–333.10.1515/hsz-2012-0332Search in Google Scholar PubMed

Potier, L., Waeckel, L., Vincent, M.P., Chollet, C., Gobeil, F., Jr., Marre, M., Bruneval, P., Richer, C., Roussel, R., Alhenc-Gelas, F., et al. (2013b). Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J. Pharmacol. Exp. Ther. 346, 23–30.10.1124/jpet.113.203927Search in Google Scholar PubMed

Regoli, D., Rizzi, A., Perron, S.I., and Gobeil, F., Jr. (2001). Classification of kinin receptors. Biol. Chem. 382, 31–35.10.1007/978-3-0348-7321-5_60Search in Google Scholar PubMed

Silvestre, J.S., Bergaya, S., Tamarat, R., Duriez, M., Boulanger, C.M., and Levy, B.I. (2001). Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B₂ receptor pathway. Circ. Res. 89, 678–683.10.1161/hh2001.097691Search in Google Scholar PubMed

Spinetti, G., Fortunato, O., Cordella, D., Portararo, P., Krankel, N., Katare, R., Sala-Newby, G.B., Richer, C., Vincent, M.P., Alhenc-Gelas, F., et al. (2011). Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ. Res. 108, 284–293.10.1161/CIRCRESAHA.110.236786Search in Google Scholar PubMed PubMed Central

Stone, O.A., Richer, C., Emanueli, C., van Weel, V., Quax, P.H., Katare, R., Kraenkel, N., Campagnolo, P., Barcelos, L.S., Siragusa, M., et al. (2009). Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler. Thromb. Vasc. Biol. 29, 657–664.10.1161/ATVBAHA.108.182139Search in Google Scholar PubMed PubMed Central

Takahashi, N., Hagaman, J.R., Kim, H.S., and Smithies, O. (2003). Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 144, 2184–2190.10.1210/en.2002-221045Search in Google Scholar PubMed

Waeckel, L., Potier, L., Chollet, C., Taveau, C., Bruneval, P., Roussel, R., Alhenc-Gelas, F., and Bouby, N. (2012). Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse. Endocrinology 153, 3886–3896.10.1210/en.2012-1225Search in Google Scholar PubMed

Waeckel, L., Potier, L., Richer, C., Roussel, R., Bouby, N., and Alhenc-Gelas, F. (2013). Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thromb. Haemost. 110, 476–483.10.1160/TH12-12-0937Search in Google Scholar PubMed

Yang, X.P., Liu, Y.H., Scicli, G.M., Webb, C.R., and Carretero, O.A. (1997). Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30, 735–740.10.1161/01.HYP.30.3.735Search in Google Scholar PubMed

Yang, X.P., Liu, Y.H., Mehta, D., Cavasin, M.A., Shesely, E., Xu, J., Liu, F., and Carretero, O.A. (2001). Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B₂ kinin receptor gene knockout mice. Circ. Res. 88, 1072–1079.10.1161/hh1001.090759Search in Google Scholar PubMed

Youcef, G., Belaidi, E., Waeckel, L., Fazal, L., Clemessy, M., Vincent, M.P., Zadigue, G., Richer, C., Alhenc-Gelas, F., Ovize, M., et al. (2015). Tissue kallikrein is required for the cardioprotective effect of cyclosporin A in myocardial ischemia in the mouse. Biochem. Pharmacol. 94, 22–29.10.1016/j.bcp.2015.01.007Search in Google Scholar PubMed